{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:12:10Z","timestamp":1787587930789,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82173102"],"award-info":[{"award-number":["No. 82173102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Androgen deprivation therapy (ADT) remains the standard treatment for advanced prostate cancer (PCa); however, most patients ultimately progress to lethal castration-resistant PCa (CRPC). Emerging evidence implicates RNA N\u2076-methyladenosine (m\u2076A) modification as a key regulator of cancer biology, yet its role in CRPC remains poorly understood. As a critical adaptor in the m\u2076A methyltransferase complex, RNA-binding motif protein 15 (RBM15) directs m\u2076A deposition to specific mRNA targets. Here, we identified RBM15 as the key methyltransferase member significantly upregulated in CRPC tissues and strongly correlated with poor patient survival. Functionally, RBM15 overexpression reduces PCa cell sensitivity to enzalutamide, whereas its knockdown suppresses tumor growth and invasion. Mechanistically, RBM15 is an androgen-responsive protein whose expression increases upon chronic androgen deprivation. It catalyzes m\u2076A methylation at position A1384 of damaged DNA binding protein 1 (\n                    <jats:italic>DDB1<\/jats:italic>\n                    ) mRNA, leading to YTHDF2-dependent transcript decay and reduced DDB1 protein levels. Lower DDB1 impairs K48-linked polyubiquitination of the androgen receptor (AR), thereby stabilizing AR and amplifying AR signaling. Importantly, AR transcriptionally activates\n                    <jats:italic>RBM15<\/jats:italic>\n                    , forming a feed-forward loop that drives CRPC progression. Collectively, our findings establish RBM15 as a central epitranscriptomic driver of CRPC and identify the RBM15\u2013DDB1\u2013AR axis as a promising therapeutic target. Dual inhibition of RBM15 and AR may offer a novel strategy to overcome treatment resistance in advanced PCa.\n                  <\/jats:p>","DOI":"10.1186\/s43556-026-00428-1","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:20:09Z","timestamp":1775640009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting the RNA-binding motif protein 15 suppresses prostate cancer progression and hormone therapy resistance by promoting androgen receptor degradation"],"prefix":"10.1186","volume":"7","author":[{"given":"Bintao","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5142-9742","authenticated-orcid":false,"given":"Le","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"3","key":"428_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"26","key":"428_CR2","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1200\/JCO.23.00433","volume":"41","author":"C Dai","year":"2023","unstructured":"Dai C, Dehm SM, Sharifi N. Targeting the androgen signaling axis in prostate cancer. J Clin Oncol. 2023;41(26):4267\u201378. https:\/\/doi.org\/10.1200\/JCO.23.00433.","journal-title":"J Clin Oncol"},{"issue":"1","key":"428_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"428_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cells13010104","author":"VA Daniels","year":"2024","unstructured":"Daniels VA, Luo J, Paller CJ, Kanayama M. Therapeutic approaches to targeting androgen receptor splice variants. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13010104.","journal-title":"Cells"},{"issue":"2","key":"428_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.tcb.2017.10.001","volume":"28","author":"DP Patil","year":"2018","unstructured":"Patil DP, Pickering BF, Jaffrey SR. Reading m(6)A in the transcriptome: m(6)A-binding proteins. Trends Cell Biol. 2018;28(2):113\u201327. https:\/\/doi.org\/10.1016\/j.tcb.2017.10.001.","journal-title":"Trends Cell Biol"},{"issue":"3","key":"428_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41576-022-00534-0","volume":"24","author":"K Boulias","year":"2023","unstructured":"Boulias K, Greer EL. Biological roles of adenine methylation in RNA. Nat Rev Genet. 2023;24(3):143\u201360. https:\/\/doi.org\/10.1038\/s41576-022-00534-0.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"428_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00298-7","volume":"11","author":"Z Fang","year":"2022","unstructured":"Fang Z, Mei W, Qu C, Lu J, Shang L, Cao F, et al. Role of m6A writers, erasers and readers in cancer. Exp Hematol Oncol. 2022;11(1):45. https:\/\/doi.org\/10.1186\/s40164-022-00298-7.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"428_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01810-1","volume":"22","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wang Y, Patel H, Chen J, Wang J, Chen ZS, et al. Epigenetic modification of m(6)A regulator proteins in cancer. Mol Cancer. 2023;22(1):102. https:\/\/doi.org\/10.1186\/s12943-023-01810-1.","journal-title":"Mol Cancer"},{"issue":"4","key":"428_CR9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.molcel.2019.04.025","volume":"74","author":"H Shi","year":"2019","unstructured":"Shi H, Wei J, He C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol Cell. 2019;74(4):640\u201350. https:\/\/doi.org\/10.1016\/j.molcel.2019.04.025.","journal-title":"Mol Cell"},{"issue":"1","key":"428_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1109-9","volume":"18","author":"L He","year":"2019","unstructured":"He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176. https:\/\/doi.org\/10.1186\/s12943-019-1109-9.","journal-title":"Mol Cancer"},{"issue":"1","key":"428_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01558-0","volume":"21","author":"X Li","year":"2022","unstructured":"Li X, Ma S, Deng Y, Yi P, Yu J. Targeting the RNA m(6)A modification for cancer immunotherapy. Mol Cancer. 2022;21(1):76. https:\/\/doi.org\/10.1186\/s12943-022-01558-0.","journal-title":"Mol Cancer"},{"issue":"1","key":"428_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01680-z","volume":"21","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zou H, Dang Q, Xu H, Liu L, Zhang Y, et al. Biological and pharmacological roles of m(6)A modifications in cancer drug resistance. Mol Cancer. 2022;21(1):220. https:\/\/doi.org\/10.1186\/s12943-022-01680-z.","journal-title":"Mol Cancer"},{"issue":"1","key":"428_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41416-023-02246-6","volume":"129","author":"MN Diao","year":"2023","unstructured":"Diao MN, Zhang XJ, Zhang YF. The critical roles of m6A RNA methylation in lung cancer: from mechanism to prognosis and therapy. Br J Cancer. 2023;129(1):8\u201323. https:\/\/doi.org\/10.1038\/s41416-023-02246-6.","journal-title":"Br J Cancer"},{"issue":"1","key":"428_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01485-z","volume":"9","author":"SQ Ding","year":"2023","unstructured":"Ding SQ, Zhang XP, Pei JP, Bai X, Ma JJ, Zhang CD, et al. Role of N6-methyladenosine RNA modification in gastric cancer. Cell Death Discov. 2023;9(1):241. https:\/\/doi.org\/10.1038\/s41420-023-01485-z.","journal-title":"Cell Death Discov"},{"key":"428_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cells11091516","author":"FM Auld","year":"2022","unstructured":"Auld FM, Sergi CM, Leng R, Shen F. The role of N(6)-methyladenosine in the promotion of hepatoblastoma: a critical review. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11091516.","journal-title":"Cells"},{"issue":"9","key":"428_CR16","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1182\/blood.2024027712","volume":"146","author":"MY Mayday","year":"2025","unstructured":"Mayday MY, Biancon G, Wei M, Ramirez C, Moratti I, Pintado-Urbanc AP, et al. RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and Wnt pathway activation. Blood. 2025;146(9):1096\u2013109. https:\/\/doi.org\/10.1182\/blood.2024027712.","journal-title":"Blood"},{"key":"428_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2023.06.024","author":"J Zhang","year":"2023","unstructured":"Zhang J, Wei J, Sun R, Sheng H, Yin K, Pan Y, et al. A lncrna from the FTO locus acts as a suppressor of the m6A writer complex and p53 tumor suppression signaling. Mol Cell. 2023. https:\/\/doi.org\/10.1016\/j.molcel.2023.06.024.","journal-title":"Mol Cell"},{"issue":"5","key":"428_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41422-018-0034-6","volume":"28","author":"X Deng","year":"2018","unstructured":"Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N(6)-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018;28(5):507\u201317. https:\/\/doi.org\/10.1038\/s41422-018-0034-6.","journal-title":"Cell Res"},{"issue":"1","key":"428_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01871-4","volume":"40","author":"X Wang","year":"2021","unstructured":"Wang X, Tian L, Li Y, Wang J, Yan B, Yang L, et al. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent. J Exp Clin Cancer Res. 2021;40(1):80. https:\/\/doi.org\/10.1186\/s13046-021-01871-4.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"428_CR20","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s12276-024-01235-w","volume":"56","author":"SH Park","year":"2024","unstructured":"Park SH, Ju J-S, Woo H, Yun HJ, Lee SB, Kim S-H, et al. The m6A writer RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolism. Exp Mol Med. 2024;56(6):1373\u201387. https:\/\/doi.org\/10.1038\/s12276-024-01235-w.","journal-title":"Exp Mol Med"},{"issue":"1","key":"428_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-02000-5","volume":"29","author":"B Hu","year":"2024","unstructured":"Hu B, Lin D, Liu Z, Chen R, Liu J, Wu Y, et al. Identification of RBM15 as a prognostic biomarker in prostate cancer involving the regulation of prognostic m6A-related lncRNAs. Eur J Med Res. 2024;29(1):411. https:\/\/doi.org\/10.1186\/s40001-024-02000-5.","journal-title":"Eur J Med Res"},{"issue":"3","key":"428_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1158\/1535-7163.MCT-14-0710","volume":"14","author":"J Canon","year":"2015","unstructured":"Canon J, Osgood T, Olson SH, Saiki AY, Robertson R, Yu D, et al. The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents. Mol Cancer Ther. 2015;14(3):649\u201358. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0710.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"428_CR23","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.biocel.2011.09.001","volume":"43","author":"B Iovine","year":"2011","unstructured":"Iovine B, Iannella ML, Bevilacqua MA. Damage-specific DNA binding protein 1 (DDB1): a protein with a wide range of functions. Int J Biochem Cell Biol. 2011;43(12):1664\u20137. https:\/\/doi.org\/10.1016\/j.biocel.2011.09.001.","journal-title":"Int J Biochem Cell Biol"},{"issue":"7620","key":"428_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nature19342","volume":"537","author":"DP Patil","year":"2016","unstructured":"Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttman M, et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016;537(7620):369\u201373. https:\/\/doi.org\/10.1038\/nature19342.","journal-title":"Nature"},{"issue":"1","key":"428_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01994-0","volume":"23","author":"Y Ying","year":"2024","unstructured":"Ying Y, Wu Y, Zhang F, Tang Y, Yi J, Ma X, et al. Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer. Mol Cancer. 2024;23(1):79. https:\/\/doi.org\/10.1186\/s12943-024-01994-0.","journal-title":"Mol Cancer"},{"issue":"9","key":"428_CR26","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1021\/acs.jproteome.8b00135","volume":"17","author":"C Tu","year":"2018","unstructured":"Tu C, Fiandalo MV, Pop E, Stocking JJ, Azabdaftari G, Li J, et al. Proteomic analysis of charcoal-stripped fetal bovine serum reveals changes in the insulin-like growth factor signaling pathway. J Proteome Res. 2018;17(9):2963\u201377. https:\/\/doi.org\/10.1021\/acs.jproteome.8b00135.","journal-title":"J Proteome Res"},{"key":"428_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215619","volume":"534","author":"F Fontana","year":"2022","unstructured":"Fontana F, Anselmi M, Limonta P. Molecular mechanisms and genetic alterations in prostate cancer: from diagnosis to targeted therapy. Cancer Lett. 2022;534:215619. https:\/\/doi.org\/10.1016\/j.canlet.2022.215619.","journal-title":"Cancer Lett"},{"issue":"24","key":"428_CR28","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"MS Litwin","year":"2017","unstructured":"Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532\u201342. https:\/\/doi.org\/10.1001\/jama.2017.7248.","journal-title":"JAMA"},{"issue":"44","key":"428_CR29","doi-asserted-by":"publisher","first-page":"36935","DOI":"10.1074\/jbc.M501725200","volume":"280","author":"E Hiriart","year":"2005","unstructured":"Hiriart E, Gruffat H, Buisson M, Mikaelian I, Keppler S, Meresse P, et al. Interaction of the Epstein-Barr virus mRNA export factor EB2 with human Spen proteins SHARP, OTT1, and a novel member of the family, OTT3, links Spen proteins with splicing regulation and mRNA export. J Biol Chem. 2005;280(44):36935\u201345. https:\/\/doi.org\/10.1074\/jbc.M501725200.","journal-title":"J Biol Chem"},{"key":"428_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041084","author":"H Dong","year":"2023","unstructured":"Dong H, Zhang H, Mao X, Liu S, Xu W, Zhang Y. RBM15 promates the proliferation, migration and invasion of pancreatic cancer cell lines. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15041084.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"428_CR31","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s12276-024-01235-w","volume":"56","author":"SH Park","year":"2024","unstructured":"Park SH, Ju JS, Woo H, Yun HJ, Lee SB, Kim SH, et al. The m(6)A writer RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolism. Exp Mol Med. 2024;56(6):1373\u201387. https:\/\/doi.org\/10.1038\/s12276-024-01235-w.","journal-title":"Exp Mol Med"},{"issue":"15","key":"428_CR32","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1016\/j.molcel.2023.06.024","volume":"83","author":"J Zhang","year":"2023","unstructured":"Zhang J, Wei J, Sun R, Sheng H, Yin K, Pan Y, et al. A lncrna from the FTO locus acts as a suppressor of the m(6)A writer complex and p53 tumor suppression signaling. Mol Cell. 2023;83(15):2692-708 e7. https:\/\/doi.org\/10.1016\/j.molcel.2023.06.024.","journal-title":"Mol Cell"},{"issue":"4","key":"428_CR33","doi-asserted-by":"publisher","first-page":"726","DOI":"10.20517\/cdr.2020.42","volume":"3","author":"M Bungaro","year":"2020","unstructured":"Bungaro M, Buttigliero C, Tucci M. Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. Cancer Drug Resist. 2020;3(4):726\u201341. https:\/\/doi.org\/10.20517\/cdr.2020.42.","journal-title":"Cancer Drug Resist"},{"issue":"3","key":"428_CR34","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/bjc.1998.71","volume":"77","author":"V Spataro","year":"1998","unstructured":"Spataro V, Norbury C, Harris AL. The ubiquitin-proteasome pathway in cancer. Br J Cancer. 1998;77(3):448\u201355. https:\/\/doi.org\/10.1038\/bjc.1998.71.","journal-title":"Br J Cancer"},{"issue":"18","key":"428_CR35","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1007\/s00018-016-2255-5","volume":"73","author":"GL Grice","year":"2016","unstructured":"Grice GL, Nathan JA. The recognition of ubiquitinated proteins by the proteasome. Cell Mol Life Sci. 2016;73(18):3497\u2013506. https:\/\/doi.org\/10.1007\/s00018-016-2255-5.","journal-title":"Cell Mol Life Sci"},{"key":"428_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111971","author":"A Sharma","year":"2021","unstructured":"Sharma A, Khan H, Singh TG, Grewal AK, Najda A, Kawecka-Radomska M, et al. Pharmacological modulation of ubiquitin-proteasome pathways in oncogenic signaling. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222111971.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"428_CR37","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.trecan.2021.05.004","volume":"7","author":"MM Pham","year":"2021","unstructured":"Pham MM, Ngoi NYL, Peng G, Tan DSP, Yap TA. Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. Trends Cancer. 2021;7(10):958\u201370. https:\/\/doi.org\/10.1016\/j.trecan.2021.05.004.","journal-title":"Trends Cancer"},{"issue":"4","key":"428_CR38","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/0008-5472.CAN-22-2801","volume":"83","author":"H Zhang","year":"2023","unstructured":"Zhang H, Jin X, Huang H. Deregulation of SPOP in cancer. Cancer Res. 2023;83(4):489\u201399. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-2801.","journal-title":"Cancer Res"},{"issue":"11","key":"428_CR39","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.tibs.2009.07.002","volume":"34","author":"S Jackson","year":"2009","unstructured":"Jackson S, Xiong Y. CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem Sci. 2009;34(11):562\u201370. https:\/\/doi.org\/10.1016\/j.tibs.2009.07.002.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"428_CR40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1021\/acschembio.3c00487","volume":"19","author":"M Meyers","year":"2024","unstructured":"Meyers M, Cismoski S, Panidapu A, Chie-Leon B, Nomura DK. Targeted protein degradation through recruitment of the CUL4 complex adaptor protein DDB1. ACS Chem Biol. 2024;19(1):58\u201368. https:\/\/doi.org\/10.1021\/acschembio.3c00487.","journal-title":"ACS Chem Biol"},{"issue":"1","key":"428_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/aps.2014.18","volume":"36","author":"MH Tan","year":"2015","unstructured":"Tan MH, Li J, Xu HE, Melcher K, Yong EL. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin. 2015;36(1):3\u201323. https:\/\/doi.org\/10.1038\/aps.2014.18.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"428_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-021-00703-w","volume":"7","author":"X Cai","year":"2021","unstructured":"Cai X, Chen Y, Man D, Yang B, Feng X, Zhang D, et al. RBM15 promotes hepatocellular carcinoma progression by regulating N6-methyladenosine modification of YES1 mRNA in an IGF2BP1-dependent manner. Cell Death Discov. 2021;7(1):315. https:\/\/doi.org\/10.1038\/s41420-021-00703-w.","journal-title":"Cell Death Discov"},{"issue":"9","key":"428_CR43","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1002\/tox.23852","volume":"38","author":"Y Song","year":"2023","unstructured":"Song Y, Wu Q. RBM15 m(6) A modification-mediated OTUB2 upregulation promotes cervical cancer progression via the AKT\/mTOR signaling. Environ Toxicol. 2023;38(9):2155\u201364. https:\/\/doi.org\/10.1002\/tox.23852.","journal-title":"Environ Toxicol"},{"issue":"16","key":"428_CR44","doi-asserted-by":"publisher","first-page":"7640","DOI":"10.7150\/thno.61178","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen Y, Pan C, Wang X, Xu D, Ma Y, Hu J, et al. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells. Theranostics. 2021;11(16):7640\u201357. https:\/\/doi.org\/10.7150\/thno.61178.","journal-title":"Theranostics"},{"issue":"11","key":"428_CR45","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1038\/s12276-023-01108-8","volume":"55","author":"J Yu","year":"2023","unstructured":"Yu J, Li W, Hou GJ, Sun DP, Yang Y, Yuan SX, et al. Circular RNA cFAM210A, degradable by HBx, inhibits HCC tumorigenesis by suppressing YBX1 transactivation. Exp Mol Med. 2023;55(11):2390\u2013401. https:\/\/doi.org\/10.1038\/s12276-023-01108-8.","journal-title":"Exp Mol Med"},{"issue":"3","key":"428_CR46","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell. 2018;174(3):758-69 e9. https:\/\/doi.org\/10.1016\/j.cell.2018.06.039.","journal-title":"Cell"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00428-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00428-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00428-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:20:10Z","timestamp":1775640010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00428-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00428-1","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"23 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments in this study were approved by the Laboratory Animal Welfare & Ethics Committee of Tongji Hospital of Huazhong University of Science and Technology (approval number TJH-202310015). All animal experiments were conducted in accordance with the Basel Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}